24th ESGLD Workshop and Graduate Course
7th to 11th September 2022
The European Study Group on Lysosomal Diseases would like to thank all our sponsors for their support of the 24th ESGLD Workshop and Graduate Course.
Aiming to be a global leader in genetic medicine
AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. Both our founder and our employees are still motivated by this desire.
Better Health, Brighter Future
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.
What if one gene can change your entire world?
At AVROBIO, we aim to halt or reverse disease with a single dose of gene therapy. Our goal is simple and powerful: We aim to enable individuals with genetic disease to live longer — free from disease progression, free from painful and debilitating symptoms and free from the burden of chronic treatment regimens.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – means that the work we do benefits all our stakeholders, including employees, partners, and patients.
We continue to build upon our 46-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. If you are interested in speaking with JCR regarding business development opportunities visit our website at https://congress.jcrpharm.co.jp
Pioneers in Rare Disease
Established in 1997, BioMarin is a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering breakthrough treatments for debilitating and life-threatening conditions where we can significantly improve upon the
Traffic is a monthly, peer-reviewed, scientific journal, which was established in 2000, and is published by Wiley-Blackwell. The online version is at the Wiley Online Library. This journal is co-edited by Eric Chevet, Antonella De Matteis, Eeva-Liisa Eskelinen, and Hesso Farhan. The journal covers all aspects of signal transduction (intracellular transport) in health and disease, for both mammalian and non-mammalian biological systems.
Our Rare Formula
Relentless dedication to serving patients with serious rare and ultra-rare genetic diseases
At Ultragenyx, we have a unique formula for drug development that reflects our shared urgency to accelerate the timelines for delivering safe and effective new medicines to patients.
For further information regarding 24th ESGLD Workshop and Graduate Course, 2022 Lancaster please contact:
Dr Tereza Andreou
School of Biological Sciences
Faculty of Biology, Medicine and Health
3.721 Stopford Building
The University of Manchester